Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
ConclusionsIn this study, we observed VTE development in more than 10% of immunotherapy-treated patients and increased VTE risk in patients with poorer ECOG status. With the asymptomatic nature of VTEs in most cases, a high index of suspicion level for VTE is required in patients treated with immunotherapy.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | Kidney Cancer | Melanoma | Pulmonary Thromboembolism | Renal Cell Carcinoma | Skin Cancer | Study | Thrombosis